Impact of three-tier pharmacy benefit structures on consumer attitudes, pharmacy, medical utilization and costs: A critical review

Disease Management and Health Outcomes

Volumn 12, Issue 2, 2004, Pages 81-92

  Nair, Kavita V ^a   Valuck, Robert J ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AGING; CHRONIC DISEASE; CLINICAL PHARMACY; CONSUMER; COST EFFECTIVENESS ANALYSIS; COST UTILITY ANALYSIS; DECISION MAKING; DRUG CHOICE; DRUG COST; DRUG PREFERENCE; FOLLOW UP; HEALTH CARE PLANNING; HEALTH CARE POLICY; HEALTH CARE UTILIZATION; HUMAN; LOWEST INCOME GROUP; PHARMACY AND THERAPEUTICS COMMITTEE; PRESCRIPTION; REVIEW; TREATMENT WITHDRAWAL;

EID: 1942436699     PISSN: 11738790     EISSN: None     Source Type: Journal    
DOI: 10.2165/00115677-200412020-00002     Document Type: Review

References (32)

1. Centers for Medicare and Medicaid Services. Table 11: prescription drug expenditures aggregate and per capita amounts, percent distribution and average percent change by source of funds (years 1980-2001). Available from URL: http://www.cms.hhs.gov/statistics/nhe/projections-2001/t11.asp [Accessed 2003 Sep 16]
2. Hibbard JH, Weeks EC. Consumerism in health care: prevalence and predictors. Med Care 1897; 25 (11): 1019-32
3. Chewning B, Sleath B. Medication decision-making and management: a client-centered model. Soc Sci Med 1996; 42 (3): 389-98
4. Novartis Pharmacy Benefit Report. 2001 edition. Facts and figures. Totowa (NJ): Emron, an IMS Health Company, 2001
5. Frank RG. Prescription drug prices: why do some pay more than others do? Health Aff 2001; 20 (2): 715-28
6. Novartis Pharmaceuticals. Novartis Pharmacy Benefit Report: Facts and Figures, 2001. Novartis Pharmaceuticals: East Hanover (NJ), 2001
7. Takedea Prescription drug benefit cost and plan design survey report. 2002 edition. Alberquerque (NM): Wellman Publishing, 2002
8. Nair KV, Ganther JM, Valuck RJ, et al. Impact of multi-tiered pharmacy benefits on attitudes of patients with chronic disease states. J Manage Care Pharm 2002 Nov/Dec; 8 (6): 477-93
9. Motheral BR, Fairman KA. Effect of a three tier prescription copay on pharmaceutical and other medical utilization. Med Care 2001; 39 (12): 1293-304
10. Nair KV, Wolfe P, Valuck RJ, et al. Effect of a three-tier pharmacy benefit design on the prescription purchasing behavior of individuals with chronic disease states. J Manage Care Pharm 2003 Mar/Apr; 2 (2): 479-89
11. Nair KV, Valuck RJ, Allen RR. Rates of continuation of non formulary medications for chronic disease sufferers in multi-tiered pharmacy benefit plans [abstract]. Poster presentation at the 8th Annual International Meeting of the International Society on Pharmacoeconomic and Outcomes Research; 2003 May 18-21; Arlington (VA)
12. Joyce GF, Escarce JJ, Solomon MD, et al. Employer drug benefit plans and spending for prescription drugs. JAMA 2002; 288 (14): 1733-9
13. Thomas CP, Wallack SS, Lee S, et al. Impact of plan design and management in retirees prescription drug use and spending, 2001. Health Aff (Millwood) 2002 Supp Web Exclusives; W408-19
14. Goldstein E, Fyock J. Reporting of CAHPS quality information to Medicare beneficiaries. Health Serv Res 2001; 36 (3): 477-88
15. Desselle SP. Determinants of satisfaction with prescription drug plans. Am J Health Syst Pharm 2001, 1110-9
16. Reissman D. Issues in drug benefit management: have we pushed member copayments too far? Drug Benefit Trends 2001; 13 (3): 13-24
17. Schneeweiss S, Maclure M, Walker AM, et al. On the evaluation of drug benefits policy changes with longitudinal claims data: the policy maker's versus the clinician's perspective. Health Policy 2001; 55: 97-109
18. Segedin DA. Three-tier copayment plans: design considerations and effectiveness. Drug Benefit Trends 1999; 11 (9): 43-52
19. Darves B. Three-tier designs show mixed results [online]. Available from URL: http://www.qualityindicator.com/cgi-bin/article.cgi?.article_id=1117 [Accessed 2003 Sep 16]
20. Tamblyn R, Laprise R, Hanley JA, et al. Adverse events associated with prescription drug cost-sharing among poor and elderly persons. JAMA 2001; 285 (4): 421-9
21. Pilote L, Beck C, Richard H, et al. The effects of cost sharing on essential drug prescriptions, utilization of medical care and outcomes after acute myocardial infarction in elderly patients. CMAJ 2002; 167: 246-52
22. Nelson A, Reeder C, Dickson W. The effect of a Medicaid co-payment program on the utilization and costs of prescription services. Med Care 1984; 22: 724-36
23. Reeder C, Nelson A. The differential impact of co-payment on drug use in a Medicaid population. Inquiry 1985; 22 (4): 396-403
24. Soumerai S, Ross-Degan D, Avorn J, et al. Payment restrictions for drugs under Medicaid: effects in therapy, cost and equity. N Engl J Med 1987; 317: 550-6
25. Harris BL, Stergachis A, Reid D. The effect of copayments on utilization and costs of pharmaceuticals in a health maintenance organization. Med Care 1990, 917
26. Smith D. The effects of copayments and generic substitution on the use and costs of prescription drugs. Inquiry 1993; 30: 189-97
27. Johnson RE, Goodman MJ, Hornbrook MC, et al. The effect of increased prescription drug cost-sharing on medical care utilization and expenses of elderly health maintenance organization members. Med Care 1997; 35 (11): 1119-31
28. Johnson RE, Goodman MJ, Hornbrook MC, et al. The impact of increasing patient prescription drug cost sharing on therapeutic classes of drugs received and on the health status of elderly HMO members. Health Serv Res 1997; 32 (1): 103-22
29. McKercher PL, Taylor SD. Exploring insurance effects on prescription drug coverage. Ann Pharmacother 2002; 36: 1805-6
30. Fendrick MA, Smith DG, Chernew ME, et al. A benefit based co-pay for prescription drugs: patient contribution based on total benefits, not drug acquisition cost. Am J Manage Care 2001; 7 (9): 861-7
31. Christianson JB, Parente ST, Taylor R. Defined contribution health insurance products: development and prospects. Health Aff (Millwood) 2002; 21 (1): 49-64
32. Swartz K. Be creative in consumer cost sharing for pharmaceutical benefits. Inquiry 1998/99; 35: 365-8